Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
GSK and Flagship to jointly fund up to $150 million upfront
Report highlights significant improvements in adolescent well-being in India
Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Subscribe To Our Newsletter & Stay Updated